Статья Рекомендации по исследованиям рецептора эпидермального фактора роста человека второго типа (her2) при раке молочной железы

27. Bowles E. J., Wellman R., Feigelson H. S., et al: Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: A retrospective cohort study. J Natl Cancer Inst 104: 1293-1305, 2012

28. Slamon D. J., Leyland-Jones B., Shak S., et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001

29. Smith I., Procter M., Gelber R. D., et al: 2-yearfollow-upoftrastuzumabafter adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 369: 29-36, 2007

30. Perez E. A., Romond E. H., Suman V. J., et al: Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31.J Clin Oncol 29: 3366-3373, 2011

31. Gianni L., Dafni U., Gelber R. D., et al: Treatmentwithtrastuzumabfor 1 year after adjuvant chemotherapy in patients with HER2-positiveearly breast cancer: A 4-yearfollow-upofarandomised controlledtrial. LancetOncol 12: 236-244, 2011

32. Geyer C. Е., Forster J., Lindquist D., et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733-2743, 2006

33. Baselga J., Cortes J., Kim S. B., et al: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366: 109-119, 2012

34. Verma S., Miles D., Gianni L., et al: Trastuzumab emtansine for HER2- positive advanced breast cancer. N Engl J Med 367: 1783-1791, 2012

35. Press M. F., Finn R. S., Cameron D., et al: HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res 14: 7861-7870, 2008

36. Gianni L., Llado A., Bianchi G., et al: Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patientswith human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28: 1131-1137, 2010

37. Hurvitz S. A., Dirix L., Kocsis J., et al: Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 31: 1157-1163, 2013

38. Paik S., Kim C., Wolmark N.: HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 358: 1409-1411, 2008

39. Middleton L. P., Price K. M., Puig P., et al: Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 guideline recommendations in a tertiary care facility increases HER2 immunohistochem- istry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases. Arch Pathol Lab Med 133: 775-780, 2009

40. Bartlett J. M., Ibrahim M., Jasani B., et al: External quality assurance of HER2 FISH and ISH testing: Three years of the UK national external quality assurance scheme. Am J Clin Pathol 131: 106-111, 2009

41. Brunelli M., Manfrin E., Martignoni G., et al: HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: Impact on selecting patients for herceptin therapy. Am J Clin Pathol 129: 907-911, 2008

42. Reiner-Concin A., Regitnig P., Dinges H. P., et al: Practice of HER-2 immunohistochemistry in breast carcinoma in Austria. Pathol Oncol Res 14: 253-259, 2008

43. Khoury T., Sait S., Hwang H., et al: Delay to formalin fixation effect on breast biomarkers. Mod Pathol 22: 1457-1467, 2009

44. Tong L. C., Nelson N., Tsourigiannis J., et al: The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: A prospective study. Am J Surg Pathol 35: 545-552, 2011

45. Hanley K. Z., Birdsong G. G., Cohen C., et al: Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas: Comparison on cell block, needle-core, and tissue block preparations. Cancer 117: 279-288, 2009

46. Arber D. A.: Effect of prolonged formalin fixation on the immunohisto- chemical reactivity of breast markers. Appl Immunohistochem Mol Morphol 10: 183-186, 2002

47. Ibarra J. A., Rogers L. W.: Fixation time does not affect expression of HER2/ neu: A pilot study. Am J Clin Pathol 134: 594-596, 2010

48. McCullough A. E., Dell'Orto P., Reinholz M. M., et al: Concordance of HER2 central assessment by two international central laboratories: A ring study within the framework of the adjuvant HER2-positive ALTTO trial (BIG2-06/N063D/ EGF106708). Cancer Res 70, 2012 (suppl 2; abstr P3-10-36)

49. Perez E. A., Dueck A. C., McCullough A. E., et al: Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. J Natl Cancer Inst 104: 159-162, 2012

50. Iorfida M., Dellapasqua S., Bagnardi V., et al: HER2-negative (1+) breast cancer with unfavorable prognostic features: To FISH or not to FISH? Ann Oncol 23: 1371-1372, 2012

51. Hameed O., Adams A. L., Baker A. C., et al: Using a higher cutoff for the percentage of HER2+ cells decreases interobserver variability in the interpretation of HER2 immunohistochemical analysis. Am J Clin Pathol 130: 425-427, 2008

52. Atkinson R., Mollerup J., Laenkholm A. V., et al: Effects of the change in cutoff values for human epidermal growth factor receptor 2 status by immunohistochemistry and fluorescence in situ hybridization: A study comparing conventional brightfield microscopy, image analysis-assisted microscopy, and interobserver variation. Arch Pathol Lab Med 135: 1010-1016, 2011

53. Gilcrease M. Z., Woodward W. A., Nicolas M. M., et al: Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer. Am J Surg Pathol 33: 759-767, 2009

54. Niikura N., Liu J., Hayashi N., et al: Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 30: 593-599, 2012

55. Vincent-Salomon A., Pierga J. Y., Couturier J., et al: HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: A possible tool for anti-HER2 therapy management? Br J Cancer 96: 654-659, 2007

56. Santiago M. P., Vazquez-Boquete A., Fernandez B., et al: Whether to determine HER2 status for breast cancer in the primary tumour or in the metastasis. Histol Histopathol 24: 675-682, 2009

57. Wilking U., Karlsson E., Skoog L., et al: HER2 status in a population-derived breast cancer cohort: Discordances during tumor progression. Breast Cancer Res Treat 125: 553-561, 2011

58. Bates M., Sperinde J., Kostler W. J., et al: Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab. Ann Oncol 22: 2014-2020, 2011

59. Lower E. E., Glass E., Blau R., et al: HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 113: 301-306, 2009

60. Guarneri V., Giovannelli S., Ficarra G., et al: Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: Impact on patient management. Oncologist 13: 838-844, 2008

61. Tapia C., Savic S., Wagner U., et al: HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res 9: R31, 2007

62. Mittendorf E. A., Wu Y., Scaltriti M., et al: Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 15: 7381-7388, 2009

63. Bartlett J. M., Ellis I. O., Dowsett M., et al: Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early- stage breast cancer suitable for cytotoxic chemotherapy. J Clin Oncol 25: 44234430, 2007

64. Amir E., Clemons M., Purdie C. A., et al: Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multidisciplinary prospective studies. Cancer Treat Rev 38: 708-714, 2012

65. Arnedos M., Nerurkar A., Osin P., et al: Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol 20: 19481952, 2009

66. Lebeau A., Turzynski A., Braun S., et al: Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies. J Clin Oncol 28: 3264-3270, 2010

67. D'Alfonso T., Liu Y. F., Monni S., et al: Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: Emerging questions and considerations addressed. Am J Surg Pathol 34: 575-581, 2010

68. Apple S. K., Lowe A. C., Rao P. N., et al: Comparison of fluorescent in situ hybridization HER-2/neu results on core needle biopsy and excisional biopsy in primary breast cancer. Mod Pathol 22: 1151-1159, 2009

69. Chivukula M., Bhargava R., Brufsky A., et al: Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) cases. Mod Pathol 21: 363-368, 2008

70. Wood B., Junckerstorff R., Sterrett G., et al: A comparison of immunohis- tochemical staining for oestrogen receptor, progesterone receptor and HER-2 in breast core biopsies and subsequent excisions. Pathology 39: 391-395, 2007

71. Zustin J., Boddin K., Tsourlakis M. C., et al: HER-2/neu analysis in breast cancer bone metastases. J Clin Pathol 62: 542-546, 2009

72. Komatsu K., Nakanishi Y., Seki T., et al: Application of liquid-based preparation to fine needle aspiration cytology in breast cancer. Acta Cytol 52: 591-596, 2008

73. Aitken S. J., Thomas J. S., Langdon S. P., et al: Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol 21: 1254-1261, 2010

74. Bilous M.: Breast core needle biopsy: Issues and controversies. Mod Pathol 23: S36-S45, 2010 (suppl 2)

75. Hammond M. E., Hayes D. F., Dowsett M., et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 134: 907-922, 2010

76. Hammond M. E., Hayes D. F., Dowsett Mю, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28: 2784-2795, 2010

77. Genentech: Highlights of prescribing information (Herceptin; trastuzu- mab) 2013. http://www.gene.com/download/pdf/herceptin_prescribing.pdf

78. Genentech: Highlights of prescribing information (Perjeta; pertuzumab) 2013. http://www.gene.com/download/pdf/perjeta_prescribing.pdf

79. Chibon F., de Mascarel I., Sierankowski G., et al: Prediction of HER2 gene status in Her2 2+ invasive breast cancer: A study of 108 cases comparing ASCO/ CAP and FDA recommendations. Mod Pathol 22: 403-409, 2009

80. Mayr D., Heim S., Weyrauch K., et al: Chromogenic in situ hybridization for Her-2/neu-oncogene in breast cancer: Comparison of a new dual-colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization. Histopathology 55: 716-723, 2009

81. Tse C. H., Hwang H. C., Goldstein L. C., et al: Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: Implications for anti-HER2 targeted therapy. J Clin Oncol 29: 4168-174, 2011

82. Vanden Bempt .I, Van Loo P., Drijkoningen M., et al: Polysomy 17 in breast cancer: Clinicopathologic significance and impact on HER-2 testing. J Clin Oncol 26: 4869-4874, 2008

83. Sinczak-Kuta A., Tomaszewska R., Rudnicka-Sosin L., et al: Evaluation of HER2/neu gene amplification in patients with invasive breast carcinoma: Comparison of in situ hybridization methods. Pol J Pathol 58: 41-50, 2007

84. Capizzi E., Gruppioni E., Grigioni A. D., et al: Real time RT-PCR approach for the evaluation of ERBB2 overexpression in breast cancer archival samples: A comparative study with FISH, SISH, and immunohistochemistry. Diagn Mol Pathol 17: 220-226, 2008

85. Powell W. C., Roche P. C., Tubbs R. R.: A new rabbit monoclonal antibody (4B5) for the immuno-histochemical (IHC) determination of the HER2 status in breast cancer: Comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility. Appl Immunohistochem Mol Morphol 16: 569, 2008

86. Nunes C. B., Rocha R. M., Reis-Filho J. S., et al: Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas. J Clin Pathol 61: 934-938, 2008

87. Gustavson M. D., Bourke-Martin B., Reilly D. M., et al: Development of an unsupervised pixel-based clustering algorithm for compartmentalization of immunohistochemical expression using Automated Quantitative Analysis. Appl Immunohistochem Mol Morphol 17: 29-337, 2009

88. Egervari K., Szollosi Z., Nemes Z.: Tissue microarray technology in breast cancer HER2 diagnostics. Pathol Res Pract 203: 169-177, 2007

89. Minot D. M., Kipp B. R., Root R. M., et al: Automated cellular imaging system III for assessing HER2 status in breast cancer specimens: Development of a standardized scoring method that correlates with FISH. Am J Clin Pathol 132: 133-138, 2009

90. Hall B. H., Ianosi-Irimie M., Javidian P., et al: Computer-assisted assessment of the human epidermal growth factor receptor 2 immunohistochemical assay in imaged histologic sections using a membrane isolation algorithm and quantitative analysis of positive controls. BMC Med Imaging 8: 11, 2008

91. Itoh H., Miyajima Y., Umemura S., et al: Lower HER-2/chromosome enumeration probe 17 ratio in cytologic HER-2 fluorescence in situ hybridization for breast cancers: Three-dimensional analysis of intranuclear localization of centromere 17 and HER-2 signals. Cancer 114: 134-140, 2008

92. Roepman P., Horlings H. M., Krijgsman O., et al: Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer. Clin Cancer Res 15: 7003-7011, 2009

93. Bartlett J. M., Campbell F. M., Ibrahim M., et al: A UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assay. Am J Clin Pathol 135: 157-162, 2011

94. Pedersen M., Rasmussen B. B.: The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer. Diagn Mol Pathol 18: 96-102, 2009

95. Francis G. D., Jones M. A., Beadle G. F., et al: Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: Correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome. Diagn Mol Pathol 18: 88-95, 2009

96. Gong Y., Sweet W., Duh Y. J., et al: Performance of chromogenic in situ hybridization on testing HER2 Status in breast carcinomas with chromosome 17 polysomy and equivocal (2+) herceptest results: A study of two institutions using the conventional and new ASCO/CAP scoring criteria. Am J Clin Pathol 132: 228236, 2009

97. Vocaturo A., Novelli F., Benevolo M., et al: Chromogenic in situ hybridization to detect HER-2/neu gene amplification in histological and ThinPrep-processed breast cancer fine-needle aspirates: A sensitive and practical method in the trastuzumab era. Oncologist 11: 878-886, 2006

98. Hanna W. M., Kwok K.: Chromogenic in-situ hybridization: A viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. Mod Pathol 19: 481-487, 2006

99. Rocha R. M., Nunes C. B., Sanches F. S., et al: Rabbit antibodies for hormone receptors and HER2 evaluation in breast cancer. Rev Assoc Med Bras 55: 163168, 2009

100. Cayre A., Mishellany F., Lagarde N., et al: Comparison of different commercial kits for HER2 testing in breast cancer: Looking for the accurate cutoff for amplification. Breast Cancer Res 9: R64, 2007

101. Garcla-Caballero T., Grabau D., Green A. R., et al: Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: A European multicentre study involving 168 specimens. Histopathology 56: 472-480, 2010

102. Di Palma S., Collins N., Faulkes C., et al: Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer. J Clin Pathol 60: 1067-1068, 2007

103. Saez A., Andreu F. J., Segul M. A., et al: HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer—A study of two hundred cases. Breast 15: 519-527, 2006

104. Baehner F. L., Achacoso N., Maddala T., et al: Human epidermal growth factor receptor 2 assessment in a case-control study: Comparison offluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. J Clin Oncol 28: 4300-4306, 2010

105. Shousha S., Peston D., Amo-Takyi B., et al: Evaluation of automated silver- enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens. Histopathology 54: 248253, 2009

106. Faratian D., Graham A., Rae F., et al: Rapid screening of tissue microarrays for Her-2 fluorescence in situ hybridization testing is an accurate, efficient and economic method of providing an entirely in situ hybridization-based Her-2 testing service. Histopathology 54: 428-432, 2009

107. Ni R., Mulligan A. M., Have C., et al: PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer. Appl Immunohistochem Mol Morphol 15: 316-324, 2007

108. Uzan C., Andre F., Scott V., et al: Fine-needle aspiration for nucleic acid- ased molecular analyses in breast cancer. Cancer 117: 32-39, 2009

109. Cuadros M., Talavera P., Lopez F. J., et al: Real-time RT-PCR analysis for evaluating the Her2/neu status in breast cancer. Pathobiology 77: 38-45, 2010

110. Susini T., Bussani C., Marini G., et al: Preoperative assessment of HER-2/ neu status in breast carcinoma: The role of quantitative real-time PCR on corebiopsy specimens. Gynecol Oncol 116: 234-239, 2010

111. Huang W., Reinholz M., Weidler J., et al: Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay. Am J Clin Pathol 134: 303-311, 2010

112. Ashok M., Griffin P., Halpern M.: Impact of clinical and non-clinical factors on the choice of HER2 test for breast cancer. Cancer Invest 28: 735-742, 2010

113. Joensuu H., Sperinde J., Leinonen M., et al: Very high quantitative tumor HER2 content and outcome in early breast cancer. Ann Oncol 22: 2007-2013, 2011

114. Monego G., Arena V., Maggiano N., et al: Borderline HER-2 breast cancer cases: Histochemical versus real-time PCR analysis and impact of different cut-off values. Scand J Clin Lab Invest 67: 402-412, 2007

115. Dobson L., Conway C., Hanley A., et al: Image analysis as an adjunct to manual HER-2 immunohistochemical review: A diagnostic tool to standardize interpretation. Histopathology 57: 27-38, 2010

116. Masmoudi H., Hewitt S. M., Petrick N., et al: Automated quantitative assessment of HER-2/neu immunohistochemical expression in breast cancer. IEEE Trans Med Imaging 28: 916-925, 2009

117. Giltnane J. M., Molinaro A., Cheng H., et al: Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer. Arch Pathol Lab Med 132: 1635-1647, 2008

118. Tubbs R. R., Pettay J. D., Swain E., et al: Automation of manual components and image quantification of direct dual label fluorescence in situ hybridization (FISH) for HER2 gene amplification: A feasibility study. Appl Immunohistochem Mol Morphol 14: 436-440, 2006

119. Skaland I., Ovestad I., Janssen E. A., et al: Digital image analysis improves the quality of subjective HER-2 expression scoring in breast cancer. Appl Immunohistochem Mol Morphol 16: 185-190, 2008

120. Skaland I., Ovestad I., Janssen E. A., et al: Comparing subjective and digital image analysis HER2/neu expression scores with conventional and modified FISH scores in breast cancer. J Clin Pathol 61: 68-71, 2008

121. Stodkowska J., Filas V., Buszkiewicz E., et al: Study on breast carcinoma Her2/neu and hormonal receptors status assessed by automated images analysis systems: ACIS III (Dako) and ScanScope (Aperio). Folia Histochem Cytobiol 48: 19-25, 2010

122. Flanagan M. B., Dabbs D. J., Brufsky A. M., et al: Histopathologic variables predict Oncotype DX recurrence score. Mod Pathol 21: 1255-1261, 2008

123. Cuzick J., Dowsett M., Pineda S., et al: Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 29: 4273-4278, 2011

124. Dabbs D.J., Klein M. E., Mohsin S. K., et al: High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: An independent quality assurance study. J Clin Oncol 29: 4279-4285, 2011

125. Nassar A., Cohen C., Siddiqui M.: Estimation of hormone receptor status and HER2 in cytologic cell blocks from breast cancer using the novel rabbit monoclonal antibodies (SP1, SP2, and SP3). Diagn Cytopathol 37: 865-870, 2009

126. Francz M., Egervari K., Kardos L., et al: Comparison of Pathvysion and Poseidon HER2 FISH assays in measuring HER2 amplification in breast cancer: A validation study. J Clin Pathol 63: 341-346, 2010

127. Bergqvist J., Ohd J. F., Smeds J., et al: Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome. Ann Oncol 18: 845-850, 2007

128. Barberis M., Pellegrini C., Cannone M., et al: Quantitative PCR and HER2 testing in breast cancer: A technical and cost-effectiveness analysis. Am J Clin Pathol 129: 563-570, 2008

129. Potemski P., Pluciennik E., Bednarek . K., et al: A comparative assessment of HER2 status in operable breast cancer by real-time RT-PCR and by immunohistochemistry. Med Sci Monit 12: MT57-MT61, 2006

130. Papouchado B. G., Myles J., Lloyd R. V., et al: Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: Comparison with FISH and assessment of interobserver reproducibility. Am J Surg Pathol 34: 767-776, 2010

131. Ricardo S. A., Milanezi F., Carvalho S. T., et al: HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas. J Clin Pathol 60: 1001-1005, 2007

132. Graham A. D., Faratian D., Rae F., et al: Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: A prospective study of the use of immunohistochemistry and fluorescence in situ hybridization. Histopathology 52: 847-855, 2008

133. Mayr D., Heim S., Werhan C., et al: Comprehensive immunohistochemical analysis of Her-2/neu oncoprotein overexpression in breast cancer: HercepTest (Dako) for manual testing and Her-2/neuTest 4B5 (Ventana) for Ventana BenchMark automatic staining system with correlation to results of fluorescence in situ hybridization (FISH). Virchows Arch 454: 241-248, 2009